pre-IPO PHARMA

COMPANY OVERVIEW

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Inflammatory Disease
  • Kidney Disease
  • Liver Disease
  • Metabolic DIsorders

  • WEBSITE

    https://pandiontx.com/


    CAREER WEBSITE

    https://pandiontx.com/careers2/


    SOCIAL MEDIA


    INVESTORS

    bioinnovation-capital polaris-partners roche-venture-fund sr-one versant-ventures


    PRESS RELEASES


    Apr 1, 2021

    Merck Completes Acquisition of Pandion Therapeutics


    Mar 16, 2021

    Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody


    Mar 4, 2021

    Merck Begins Tender Offer to Acquire Pandion Therapeutics


    Mar 1, 2021

    PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick and Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND


    Feb 27, 2021

    SHAREHOLDER ALERT: Monteverde and Associates PC Announces an Investigation of Pandion Therapeutics, Inc. - PAND


    For More Press Releases


    Google Analytics Alternative